BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35322192)

  • 1. LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage.
    Latchmansingh KA; Wang X; Verdun RE; Marques-Piubelli ML; Vega F; You MJ; Chapman J; Lossos IS
    Mod Pathol; 2022 Sep; 35(9):1220-1226. PubMed ID: 35322192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
    McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
    Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.
    Shields BJ; Alserihi R; Nasa C; Bogue C; Alexander WS; McCormack MP
    Leukemia; 2015 Apr; 29(4):927-38. PubMed ID: 25283843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia.
    Li L; Mitra A; Cui K; Zhao B; Choi S; Lee JY; Stamos DB; El-Khoury D; Warzecha C; Pfeifer K; Hardwick J; Zhao K; Venters B; Davé UP; Love PE
    Blood; 2020 Jun; 135(25):2252-2265. PubMed ID: 32181817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms.
    Goossens S; Wang J; Tremblay CS; De Medts J; T'Sas S; Nguyen T; Saw J; Haigh K; Curtis DJ; Van Vlierberghe P; Berx G; Taghon T; Haigh JJ
    Haematologica; 2019 Aug; 104(8):1608-1616. PubMed ID: 30679322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels.
    Miyashita K; Kitajima K; Goyama S; Kitamura T; Hara T
    Biochem Biophys Res Commun; 2018 Jan; 495(3):2310-2316. PubMed ID: 29278703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.
    Smith S; Tripathi R; Goodings C; Cleveland S; Mathias E; Hardaway JA; Elliott N; Yi Y; Chen X; Downing J; Mullighan C; Swing DA; Tessarollo L; Li L; Love P; Jenkins NA; Copeland NG; Thompson MA; Du Y; Davé UP
    PLoS One; 2014; 9(1):e85883. PubMed ID: 24465765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal.
    McCormack MP; Young LF; Vasudevan S; de Graaf CA; Codrington R; Rabbitts TH; Jane SM; Curtis DJ
    Science; 2010 Feb; 327(5967):879-83. PubMed ID: 20093438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.
    Malumbres R; Fresquet V; Roman-Gomez J; Bobadilla M; Robles EF; Altobelli GG; Calasanz MJ; Smeland EB; Aznar MA; Agirre X; Martin-Palanco V; Prosper F; Lossos IS; Martinez-Climent JA
    Haematologica; 2011 Jul; 96(7):980-6. PubMed ID: 21459790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the
    Rahman S; Magnussen M; León TE; Farah N; Li Z; Abraham BJ; Alapi KZ; Mitchell RJ; Naughton T; Fielding AK; Pizzey A; Bustraan S; Allen C; Popa T; Pike-Overzet K; Garcia-Perez L; Gale RE; Linch DC; Staal FJT; Young RA; Look AT; Mansour MR
    Blood; 2017 Jun; 129(24):3221-3226. PubMed ID: 28270453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic dysregulation of ZEB1 is involved in LMO2-promoted T-cell acute lymphoblastic leukaemia leukaemogenesis.
    Wu C; Li J; Tian C; Shi W; Jiang H; Zhang Z; Wang H; Zhang Q; Sun W; Sun P; Xiang R; Yang S
    Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2511-2525. PubMed ID: 29778661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements.
    Homminga I; Vuerhard MJ; Langerak AW; Buijs-Gladdines J; Pieters R; Meijerink JP
    Haematologica; 2012 Feb; 97(2):258-61. PubMed ID: 22058201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.
    Shams TM
    J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.
    Morishima T; Krahl AC; Nasri M; Xu Y; Aghaallaei N; Findik B; Klimiankou M; Ritter M; Hartmann MD; Gloeckner CJ; Stefanczyk S; Lindner C; Oswald B; Bernhard R; Hähnel K; Hermanutz-Klein U; Ebinger M; Handgretinger R; Casadei N; Welte K; Andre M; Müller P; Bajoghli B; Skokowa J
    Blood; 2019 Oct; 134(14):1159-1175. PubMed ID: 31366618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.
    Calero-Nieto FJ; Joshi A; Bonadies N; Kinston S; Chan WI; Gudgin E; Pridans C; Landry JR; Kikuchi J; Huntly BJ; Gottgens B
    Oncogene; 2013 Nov; 32(48):5471-80. PubMed ID: 23708655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.
    Cerhan JR; Natkunam Y; Morton LM; Maurer MJ; Asmann Y; Habermann TM; Vasef MA; Cozen W; Lynch CF; Allmer C; Slager SL; Lossos IS; Chanock SJ; Rothman N; Hartge P; Dogan A; Wang SS
    Leuk Lymphoma; 2012 Jun; 53(6):1105-12. PubMed ID: 22066713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of cryptic chromosomal rearrangements involving the LMO2 gene in T-cell acute lymphoblastic leukemia.
    Wu L; Xu Y; Wang Q; Ruan C; Drexler HG; Wu D; MacLeod RA; Chen S
    Haematologica; 2015 Jun; 100(6):e233-6. PubMed ID: 25682596
    [No Abstract]   [Full Text] [Related]  

  • 18. Simultaneous rearrangements of TAL1 and LMO2 in T-cell acute lymphoblastic leukemia.
    Kim HK; Lim JH; Koh KN; Chi HS; Seo EJ
    Int J Lab Hematol; 2014 Oct; 36(5):e69-70. PubMed ID: 24330618
    [No Abstract]   [Full Text] [Related]  

  • 19. Overexpression of LMO2 causes aberrant human T-Cell development in vivo by three potentially distinct cellular mechanisms.
    Wiekmeijer AS; Pike-Overzet K; Brugman MH; van Eggermond MCJA; Cordes M; de Haas EFE; Li Y; Oole E; van IJcken WFJ; Egeler RM; Meijerink JP; Staal FJT
    Exp Hematol; 2016 Sep; 44(9):838-849.e9. PubMed ID: 27302866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations.
    Brar N; Butzmann A; Kumar J; Peerani R; Morgan EA; Grigoriadis G; Kumar B; Tatarczuch RM; Warnke RA; Ohgami RS
    Histopathology; 2020 Dec; 77(6):984-988. PubMed ID: 32526041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.